LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) — KabaFusion, a nationally recognized leader in home and alternative site infusion, today announced it has closed on a transaction with Coram pursuant to which it has acquired 6 locations that will serve as pharmacies and ambulatory infusion suites, which transaction is consistent with Coram’s previously announced downsizing.
September 12, 2024 – Capital Analytics Association Invest Spotlight On: Sohail Masood, Founder, Chairman & CEO, KabaFusion
Capital Analytics Association Invest Spotlight Read More »
July 30, 2024 – KabaFusion Selected by GC Biopharma USA, Inc. as a Limited Distribution Partner for Partner of ALYGLO™ for Adults With Primary Humoral Immunodeficiency (PI)
KabaFusion Selected by GC Biopharma as a Limited Distribution Partner Read More »
August 2, 2023 –
KabaFusion, a nationally recognized leader in home infusion, has been selected by UCB as a limited distribution partner to provide RYSTIGGO® (rozanolixizumab-noli).
KabaFusion Selected by UCB as a Limited Distribution Partner Read More »
